S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Scopus BioPharma Stock Forecast, Price & News

-0.06 (-1.48 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume55,138 shs
Average Volume479,298 shs
Market Capitalization$72.20 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SCPS News and Ratings via Email

Sign-up to receive the latest news and ratings for Scopus BioPharma and its competitors with MarketBeat's FREE daily newsletter.

About Scopus BioPharma

Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Current Symbol
Year Founded

Sales & Book Value

Annual Sales





Market Cap
$72.20 million
Next Earnings Date
Not Optionable


Overall MarketRank

1.93 out of 5 stars

Medical Sector

664th out of 1,361 stocks

Analyst Opinion: 3.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Scopus BioPharma (NASDAQ:SCPS) Frequently Asked Questions

Is Scopus BioPharma a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scopus BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Scopus BioPharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SCPS, but not buy additional shares or sell existing shares.
View analyst ratings for Scopus BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than Scopus BioPharma?

Wall Street analysts have given Scopus BioPharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Scopus BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Scopus BioPharma?

Scopus BioPharma saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 119,100 shares, an increase of 88.2% from the September 15th total of 63,300 shares. Based on an average trading volume of 448,600 shares, the short-interest ratio is presently 0.3 days. Currently, 2.7% of the shares of the stock are sold short.
View Scopus BioPharma's Short Interest

What price target have analysts set for SCPS?

1 brokers have issued 12 month target prices for Scopus BioPharma's shares. Their forecasts range from $20.00 to $20.00. On average, they expect Scopus BioPharma's stock price to reach $20.00 in the next year. This suggests a possible upside of 401.3% from the stock's current price.
View analysts' price targets for Scopus BioPharma
or view top-rated stocks among Wall Street analysts.

Who are Scopus BioPharma's key executives?

Scopus BioPharma's management team includes the following people:
  • Mr. Robert J. Gibson, Vice Chairman, Sec. & Treasurer
  • Mr. Ashish Pradip Sanghrajka, Pres & Director (Age 47, Pay $600k)
  • Mr. Ira Scott Greenspan, Sr. Advisor & Director (Age 62, Pay $180k)
  • Mr. Daniel J. Politzer C.F.A., CFO & COO (Age 52)
  • Mr. David Silberg, Sr. Advisor (Age 72)

What is Scopus BioPharma's stock symbol?

Scopus BioPharma trades on the NASDAQ under the ticker symbol "SCPS."

How do I buy shares of Scopus BioPharma?

Shares of SCPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scopus BioPharma's stock price today?

One share of SCPS stock can currently be purchased for approximately $3.99.

How much money does Scopus BioPharma make?

Scopus BioPharma has a market capitalization of $72.20 million.

How many employees does Scopus BioPharma have?

Scopus BioPharma employs 1 workers across the globe.

What is Scopus BioPharma's official website?

The official website for Scopus BioPharma is scopusbiopharma.com.

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.